In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
Sign Up to like & getrecommendations! Published in 2021 at "Diagnostic microbiology and infectious disease"
DOI: 10.1016/j.diagmicrobio.2021.115327
Abstract: Cefepime/zidebactam is in clinical development for the treatment of carbapenem-resistant Gram-negative infections. MICs of cefepime/zidebactam (1:1) and comparators against Enterobacterales (n = 563), Pseudomonas (n = 172) and Acinetobacter baumannii (n =181) collected from 15… read more here.
Keywords: gram negative; activity; resistance; zidebactam ... See more keywords
In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkac110
Abstract: Abstract Objectives Ertapenem has proven to be an effective antimicrobial; however, increasing enzyme-mediated resistance has been noted. Combination with zidebactam, a β-lactam enhancer, is restorative. Human-simulated regimens (HSRs) of ertapenem and zidebactam alone and in… read more here.
Keywords: zidebactam; ertapenem zidebactam; efficacy; wck 6777 ... See more keywords
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkw593
Abstract: Objectives Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent 'enhancer' effect, potentiating β-lactams targeting PBP3. We tested a novel… read more here.
Keywords: class; antibacterial activity; zidebactam; cefepime zidebactam ... See more keywords
Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cellular and Infection Microbiology"
DOI: 10.3389/fcimb.2022.918868
Abstract: Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii. Diazabicyclooctane (DBO) β-lactamase inhibitors, such as avibactam (AVI), when combined… read more here.
Keywords: sulbactam; zidebactam; combination; sulbactam susceptibility ... See more keywords